Platelets are small blood components that play indispensable roles in the initial stages of coagulation. In addition to their role in haemostasis, platelets participate in inflammation and tissue regeneration under physiological conditions. Recent studies also revealed the role of platelets under pathological conditions, including the oncogenic process. Platelets enhance tumour growth and metastasis by secreting many growth factors and angiogenic factors or by forming a coat around tumour cells in the blood stream. We previously discovered Aggrus (also known as podoplanin, gp36, gp38P, T1alpha and OTS-8) expressed on tumour cell surfaces as a key molecule for tumourinduced platelet aggregation. Aggrus expression is increased in various malignant tumours such as squamous cell carcinomas, mesotheliomas, glioblastomas and osteosarcomas. Detailed analysis revealed that Aggrus contains three tandem repeats of platelet aggregation-stimulating (PLAG) domains that are associated with its platelet aggregation-inducing ability. PLAG domains of Aggrus are involved in binding to its platelet receptor, C-type lectin-like receptor 2 (CLEC-2). Neutralizing monoclonal antibodies that interfere with AggrusCLEC-2 binding attenuate Aggrus-induced platelet aggregation, tumour cell growth and metastasis formation. Aggrus is also expressed in advanced atherosclerotic lesions, suggesting that Aggrus is associated with thrombus formation on disrupted atherosclerotic lesions. These data suggest that Aggrus is a promising cell surface target for developing new therapies against cancer and thrombosis.
Metastasis is the main cause of death in patients with cancer. Although many new molecular targeting drugs are being developed, we are still unable to manage cancers after metastasis has occurred. The process of haematogenous metastasis is complex and consists of the following steps: (i) detachment of tumour cells from the primary site, (ii) invasion into host blood vessels (intravasation), (iii) transport through circulation, (iv) arrest in or adhesion to microcapillaries in a distant organ, (v) extravasation and (vi) migration and proliferation within foreign tissues ( Fig. 1 ) (1, 2) . Passage through these complicated steps may result in the selection of multifunctional malignant tumour cells. In particular, 50.1% tumour cells survive after 24 h in circulation (3) . Thus, tumour cells receive strong selection pressures such as shear stress and immunologic assault during transport through circulation.
Platelets are small blood components that play an important role in the initial stages of haemostasis. When platelets are activated, they release hundreds of factors, including transforming growth factor (TGF), platelet-derived growth factor, matrix metalloproteinases, ADP and chemokines from alpha-granules, dense granules and lysosomes ( Fig. 1) . Platelets are well known to be associated with oncogenic processes, including tumour growth, metastasis and tumour vascular homeostasis (4, 5) . Tumours may receive such factors for their growth by inducing platelet aggregation. Another mechanism is related to achieving enhanced cancer cell embolization in the microvasculature and protection from immunological assault in circulation by forming large cancer cellplatelet aggregates. Many types of cancers are reported to be associated with a high incidence of venous thrombosis, suggesting that such cancers possessed platelet aggregation-inducing ability (4, 6) . Certain promising effects of anti-platelet or anticoagulant drugs on the prolongation of patient survival have been observed in advanced cancer (7) . However, some patients cannot take such drugs for metastasis suppression because many patients suffer thrombocytopenia caused by chemotherapeutic drug toxicity. Therefore, a novel and more elegant approach to inhibit tumour metastasis in patients with cancer would be a targeting therapy against platelet aggregation-inducing factor dominantly expressed on metastatic tumour cells.
Membrane Proteins with Platelet Aggregation-Inducing Ability
A number of tumour cell lines from various organs and species have been examined for their ability to induce platelet aggregation. Some molecules associated with tumour-induced platelet aggregation have been identified (8) using in vivo and in vitro models. For example, thrombin generation, ADP secretion and direct interaction reportedly induce platelet aggregation. With respect to direct interaction, GPIba (9), Necl-5 (10), sialyl Lewis x /sialyl Lewis a (11, 12) and integrins (13) expressed on tumour cells have been identified as the molecules associated with the tumourplatelet interaction.
To identify new metastasis-related molecules, we tried to establish metastatic variants from the mouse colon adenocarcinoma 26 cell line, which is a chemically induced undifferentiated carcinoma cell line (14) . We obtained several clones with different metastatic abilities, including highly metastatic NL-17 and poorly metastatic NL-14 cells after repeated in vivo selection and subsequent in vitro cloning (Fig. 2)  (15, 16) . Biochemical characterization of the clones revealed that their platelet aggregation-inducing ability was closely related to the metastasis-forming ability of the established variants ( Fig. 2) (17) . As membrane fractions of the highly metastatic NL-17 clone could also induce platelet aggregation, we speculated that an unknown membrane molecule (Aggrus) is associated with platelet aggregation and tumour metastasis. To identify the molecule(s), we immunized rats with NL-17 cells and tried to establish hybridomas producing monoclonal antibodies (mAbs) that specifically recognize highly metastatic NL-17 but not poorly metastatic NL-14 cells. We successfully established 8F11 mAb recognizing membrane proteins with a molecular weight of 44,000 (18) . The mouse B16 melanoma cell lines (2) , which are widely used metastatic cancer cells, are reported to have platelet aggregation-inducing ability (19) . In addition, 8F11 mAb also recognized a cell surface protein with a molecular weight of 41,000 in three metastatic variants, B16-F1, B16-F10 and B16-BL6 cells, but not in poorly metastatic parental B16 cells (20) . Interestingly, in vitro, 8F11 mAb suppressed platelet aggregation induced by the highly metastatic variant NL-17 (18) and highly metastatic variant of B16 melanoma (B16-F10) under conditions preventing thrombin activity (20) . Moreover, 8F11 mAb suppressed N. Fujita and S. Takagi pulmonary metastasis of NL-17 cells in vivo (21) . These data strongly indicate that the antigen of 8F11 mAb is a metastasis-related platelet aggregationinducing factor, Aggrus (formerly named gp44 or gp41), expressed on tumour cells.
Molecular Identification and Characterization of the Platelet Aggregation-Inducing Factor Aggrus
Using 8F11 mAb affinity column chromatography, the antigen was purified and its platelet aggregationinducing ability was confirmed (22) . Aggrus-induced platelet aggregation could be initiated without plasma components, suggesting that Aggrus may induce platelet aggregation by directly binding to its unknown platelet receptor. Unfortunately, we could not obtain a peptide sequence from the purified mouse Aggrus protein. Thus, a lot time was required to obtain Aggrus cDNA (1) .
In 2003, we successfully obtained Aggrus cDNA and confirmed its platelet aggregation-inducing ability by transfecting mouse and human Aggrus cDNA into Chinese hamster ovary (CHO) cells (23) . From the sequence of Aggrus, Aggrus was found to be identical to the previously reported lymphatic endothelial marker protein podoplanin (also called gp36, gp38P, OTS-8, PA2.26 antigen, E11 antigen or T1alpha) (1) . Aggrus/podoplanin is a type-I transmembrane sialomucin-like glycoprotein consisting of an NH 2 -terminal signal peptide (SP), an extracellular domain, a single transmembrane domain (TM) and a short cytoplasmic tail with a putative phosphorylation site (Fig. 3) . Sequence analysis indicates that Aggrus does not contain domains predictive of its function. Thus, the physiological role of Aggrus has long been unidentified. From analysis of the 8F11 mAb epitope, Aggrus was found to contain three tandem repeats of the segment EDXXVTPG (where X may be any amino acid) in the extracellular domain (Fig. 3) . In addition, 8F11 mAb recognized the second segment and suppressed Aggrus-induced platelet aggregation. We therefore referred to the segments as platelet aggregationstimulating (PLAG) domains (23) . PLAG domains were structurally and functionally conserved in humans, dogs and rodents (24) . However, there are no other proteins containing PLAG-like domains.
A striking feature of Aggrus is that it contains a high content of serine and threonine residues as potential O-glycosylation sites in an extracellular domain. Aggrus, expressed on highly metastatic tumour cells, was certainly O-glycosylated because it reacted with Wheat germ agglutinin (20) . Glycans attached to Aggrus play an important role in exhibiting its platelet aggregation-inducing ability because O-glycanase treatment resulted in loss of platelet aggregationinducing ability (22) . Using a series of glycosylationdeficient CHO cell mutants and genetically engineered yeast, the requirement of O-glycosylation has been reported for exhibiting the platelet aggregation-inducing ability of Aggrus (25, 26) . To clarify the possible link between O-glycans and PLAG domains, we generated several Aggrus point mutants in which the putative O-glycosylated threonine residues around PLAG domains were converted to alanine. As expected, mutation of threonine residues conserved in PLAG domains resulted in loss of both platelet-aggregating and metastasis-promoting abilities (Fig. 3) (27) . These results suggest that 8F11 mAb may exhibit its platelet aggregation-neutralizing activity by conformationally interfering with O-glycans attached to threonine residues in PLAG domains. Because overexpression of point mutants lacking platelet aggregation-inducing ability could not enhance the formation of pulmonary metastasis, it can be said that the platelet aggregation-inducing activity of Aggrus is directly linked to metastasis (27) .
Identification of the Aggrus Receptor on Platelets
Mice deficient in Aggrus/podoplanin die at birth from respiratory failure and have marked defects in lymphatic vessel patterning (2830). Both defects are now considered to be caused by defects in the separation of lymphatic vessels from blood vessels that rely on platelet activation (30) . Several reports suggest that Aggrus/ podoplanin is bound to the extracellular matrix (ECM; e.g. fibronectin and collagen type I) (28) and to some membrane proteins (e.g. CD44, CD9, galectin-8 and CCL21) (3134) through its extracellular domain. However, these ECM and proteins may not act as Aggrus receptors on platelets. In 2007, a nonclassical C-type lectin, C-type lectin-like receptor 2 (CLEC-2), was identified as a platelet receptor of Aggrus (35) . CLEC-2 was previously identified as a platelet receptor for the snake venom toxin rhodocytin (36) . Similarities between rhodocytin-and Aggrus-induced platelet aggregation led to the identification of CLEC-2 as a platelet receptor of Aggrus (35) . Moreover, phenotypic similarities between CLEC-2-deficient mice and Aggrus/podoplanin knockout mice (37, 38) confirmed that CLEC-2 functions as a platelet receptor of Aggrus in vivo.
CLEC-2 is also associated with Aggrus-mediated platelet aggregation under pathological conditions because antihuman Aggrus mAbs generated by immunizing PLAG domains into mouse (e.g. P2-0 mAb) (39) or rats (e.g. NZ-1 mAb) (40) could suppress CLEC-2 binding to Aggrus, platelet aggregation and pulmonary metastasis. Screening of the PLAG-binding domain in CLEC-2 revealed that a C-type lectin-like domain (CTLD), homologous to the carbohydrate recognition domain of classical C-type lectins was associated with binding to PLAG domains in Aggrus (41) . Recombinant Aggrus-induced platelet aggregation could be enhanced through formation of larger complexes by cross-linking with second antibodies. This fact is consistent with the finding that CLEC-2 transmits platelet activation signals after CLEC-2 oligomerization (42) . Therefore, Aggrus may generate platelet-aggregating signals not only by binding to CTLD in CLEC-2 but also by forming CLEC-2 clusters on the platelet surface.
Platelet-aggregating signals following Aggrus ligation were mediated by Syk, Src family kinases and phospholipase Cg2 (37). CLEC-2 À/À platelets respond normally to classical platelet agonists such as collagen, thrombin and ADP, and bind normally to collagen, laminin, fibrinogen and von Willebrand factor (37), indicating that inhibition of the AggrusCLEC-2 interaction may not affect physiological haemostasis.
Targeting Aggrus for Developing New Anti-Metastatic and Anti-Tumour Therapies
Aggrus is known to be expressed in many tumours, including squamous cell carcinomas, tumours of the central nervous systems and germ cell tumours (1, 38) . In some tumours, Aggrus expression was associated with poor outcome. Elevated Aggrus expression in cancer-associated fibroblast (CAF) was also reported, and Aggrus expression in CAFs predicts poor prognosis of lung adenocarcinomas (43) . Although precise mechanisms of Aggrus induction in these cells are unknown, TGF-b, EGF, bFGF, v-Src, AP-1 and SP1/SP3 are reportedly associated with its expression (4446). In addition to platelet-aggregating ability, Aggrus expression is known to regulate cell migration. Although the cytoplasmic tail of Aggrus is very short (Fig. 3) , Aggrus forms a complex with ezrinradixinmoesin (ERM) family proteins (47) . The binding to and activation of ERM was reported to be essential for RhoA activation and epithelialmesenchymal transition (EMT). EMT is well known to change noninvasive tumour cells to invasive ones by changing morphology and cell architecture. TGF-b is an EMT inducer in various cell types and is secreted after platelet aggregation (48) . Therefore, Aggrus expression is associated with cell migration directly (through binding to ERM proteins) and indirectly (by inducing platelet aggregation following TGF-b secretion).
Aggrus may be a therapeutic target for developing new anti-metastatic and anti-tumour drugs because Aggrus overexpression was found in various cancers (1, 38) and inhibition of the AggrusCLEC-2 interaction may not affect physiological haemostasis (37) . We previously obtained 8F11 mAb that could suppress Aggrus-induced platelet aggregation and pulmonary metastasis. Unfortunately, 8F11 mAb could recognize mouse Aggrus but not human Aggrus (23) . Thus, we recently established mouse anti-human Aggrus mAb P2-0 possessing platelet-neutralizing and metastasisinhibitory activities (39) . This antibody recognized the region around PLAG2 and PLAG3 domains. Detailed mapping of the P2-0 epitope revealed that P2-0 mAb recognized the perimeter structure around Gly 45 , Asp 48 and Asp 49 (39) . Mutations at Gly 45 or Asp 49 attenuated P2-0 mAb recognition but not its platelet aggregation-inducing or metastasis-promoting ability (Fig. 4) . Because P2-0 mAb suppressed lung metastasis of CHO cells expressing WT-Aggrus but not G45A-or D49A-Aggrus, recognition and inhibition of Aggrus is required to exhibit the anti-metastatic ability of P2-0 mAb. Rat mAb NZ-1 also reportedly suppresses Aggrus-induced platelet aggregation and tumour metastasis (40) . We have developed chimeric humanized anti-human Aggrus mAb hP2-0 by fusing the complementarity-determining region (CDR) domain of mouse P2-0 mAb with the human IgG1 Fc domain (39) . Although P2-0 mAb did not exhibit antibody-dependent cellular cytotoxicity (ADCC) nor complement-dependent cytotoxicity (CDC) activities because of its subclass (mouse IgG1), the generated hP2-0 mAb exhibits strong ADCC and CDC activities in vitro. Thus, we should assess the efficacy and safety of Aggrus-targeting cancer therapy using chimeric humanized hP2-0 mAb or newly established neutralizing mAbs of the mouse IgG2a subclass (data not shown).
Concluding Remarks
From the establishment and biochemical analysis of metastatic tumours, we succeeded to clone a new platelet aggregation-inducing factor, Aggrus/podoplanin. Since its discovery, many researchers have aimed to clarify the function of Aggrus and its platelet receptor under physiological and pathological conditions. In this review, we focused on the function of Aggrus/ podoplanin in tumour metastasis and growth. However, recent findings suggest that Aggrus is associated with thrombus formation on disrupted atherosclerotic lesions, extravascular platelet activation during clotting and wound healing (49, 50) . We have also reported that venous thrombosis is directly induced by Aggrus-expressing tumour cluster containing platelets (24) . Neutralizing anti-Aggrus mAbs may not be appropriate for treating or preventing such diseases because of its high cost. Thus, in future, we should develop small molecular inhibitors that interfere with AggrusCLEC-2 binding as new anti-platelet drugs. P2-0 mAb suppressed Aggrus-mediated pulmonary metastasis by binding to its specific epitope. P2-0 is a mouse mAb that suppresses Aggrus-induced platelet aggregation and Aggrus-mediated pulmonary metastasis. Epitope mapping analysis using recombinant Aggrus proteins revealed that P2-0 mAb recognized the perimeter structure around Gly 45 , Asp 48 and Asp
49
. Consistent with the previous experiment, P2-0 mAb could hardly or could not recognize Aggrus proteins harbouring mutations at Gly 45 (G45A) or Asp 49 (D49A), respectively, when expressed in CHO cells (upper left). Mutations at Gly 45 or Asp 49 do not attenuate platelet aggregation-inducing ability (data not shown) or metastasis-promoting ability (lower panels). The recognition capability of D2-40 mAb was not affected by mutations at Gly 45 and Asp 49 because it recognized a different epitope. Western blot analysis using D2-40 mAb confirmed equal amount of wild-type and mutant Aggrus expressions in transfected CHO cells. Consistent with the reactivity to P2-0 mAb, pulmonary metastasis of CHO cells expressing G45A-Aggrus or D49A-Aggrus could hardly or could not be suppressed by P2-0 mAb treatment (3 mg/mouse). Thus, P2-0 mAb binding to its specific epitope on Aggrus is required to suppress Aggrus-induced platelet aggregation and tumour metastasis.
